IBEDEBI Trademark

Trademark Overview


On Thursday, December 17, 2020, a trademark application was filed for IBEDEBI with the United States Patent and Trademark Office. The USPTO has given the IBEDEBI trademark a serial number of 90390261. The federal status of this trademark filing is FIFTH EXTENSION - GRANTED as of Wednesday, July 10, 2024. This trademark is owned by Celgene Corporation. The IBEDEBI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Phar...
ibedebi

General Information


Serial Number90390261
Word MarkIBEDEBI
Filing DateThursday, December 17, 2020
Status734 - FIFTH EXTENSION - GRANTED
Status DateWednesday, July 10, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 30, 2021

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; monoclonal antibodies

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, February 27, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCelgene Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Trademark Events


Event DateEvent Description
Monday, April 12, 2021ASSIGNED TO EXAMINER
Monday, April 19, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, December 21, 2020NEW APPLICATION ENTERED
Saturday, February 27, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, April 19, 2021NON-FINAL ACTION WRITTEN
Monday, April 19, 2021NON-FINAL ACTION E-MAILED
Tuesday, October 19, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, October 19, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, October 20, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, October 25, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, July 11, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, November 10, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 30, 2021PUBLISHED FOR OPPOSITION
Tuesday, November 30, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 25, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, July 13, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, January 23, 2023SOU TEAS EXTENSION RECEIVED
Monday, July 11, 2022SOU EXTENSION 1 FILED
Monday, July 11, 2022SOU EXTENSION 1 GRANTED
Monday, January 23, 2023SOU EXTENSION 2 FILED
Monday, January 23, 2023SOU EXTENSION 2 GRANTED
Monday, July 10, 2023SOU TEAS EXTENSION RECEIVED
Monday, July 10, 2023SOU EXTENSION 3 FILED
Monday, July 10, 2023SOU EXTENSION 3 GRANTED
Wednesday, January 3, 2024SOU EXTENSION 4 FILED
Wednesday, January 3, 2024SOU EXTENSION 4 GRANTED
Friday, January 5, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 25, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 12, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 3, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, July 10, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, July 10, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 10, 2024SOU EXTENSION 5 FILED
Wednesday, July 10, 2024SOU EXTENSION 5 GRANTED